Although the majority of both EGFR and KRAS mutant cases were M1b, only 2/22 (9%) EGFR mutant cases had the primary tumor resected versus 4/8 (50%) KRAS mutant patients (Supplementary Tables 1 and 2). This evidence concerns the gene KRAS and neoplasm.